References
- Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 2012;30:2046-54. https://doi.org/10.1200/JCO.2011.38.4032
- Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54. https://doi.org/10.1056/NEJMoa1200690
- Brahmer JR, Horn L, Antonia SJ, Spigel D, Ghandi L, Sequist LV, et al. Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with non-small cell lung cancer (NSCLC): overall survival and long-term safety in a phase 1 trial. In: IASLC 15th World Conference on Lung Cancer; 2013 Oct 27-30; Sydney, Australia. MO18.03.
- Antonia SJ, Grosso JF, Horak CE, Harbison CT, Kurland JF, Inzunza HD, et al. Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients with non-small cell lung cancer (NSCLC) treated with nivolumab (ANTI-PD-1; BMS-936558; ONO-4538). In: IASLC 15th World Conference on Lung Cancer; 2013 Oct 27-30; Sydney, Australia. P2.11-035.
- Garon EB, Balmanoukian A, Hamid O, Hui R, Gandhi L, Leighl N. Preliminary clinical safety and activity of MK-3475 monotherapy for the treatment of previously treated patients with non-small cell lung cancer (NSCLC). In: IASLC 15th World Conference on Lung Cancer; 2013 Oct 27-30; Sydney, Australia. MO18.02.
- Spigel DR, Gettinger SN, Horn L, Herbst RS, Gandhi L, Gordon MS, et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2013; 31(Suppl):Abstr 8008.
- Horn L, Herbst RS, Spiegel D, Gettinger SN, Gordon MS, Hollebecque A, et al. An analysis of the relationship of clinical activity to baseline EGFR status, PD-L1 expression and prior treatment history in patients with non-small cell lung cancer (NSCLC) following PD-L1 blockade with MPDL3280A (anti-PDL1). In: IASLC 14th World Conference on Lung Cancer; 2011 Jul 2-5; Amsterdam, the Netherlands. MO18.01.
- Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-65. https://doi.org/10.1056/NEJMoa1200694
- Khleif SN, Lutzky J, Segal NH, Antonia S, Blake-Haskins A, Stewart R, et al. MEDI4736, an anti-PD-L1 antibody with modified Fc domain: preclinical evaluation and early clinical results from a phase I study in patients with advanced solid tumors. In: Proceedings from the European Cancer Congress 2013; 2013 Sep 27-Oct 1; Amsterdam, The Netherlands. Abstract No. 802.
- Vansteenkiste J, Zielinski M, Linder A, Dahabreh J, Gonzalez EE, Malinowski W, et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. J Clin Oncol 2013;31:2396-403. https://doi.org/10.1200/JCO.2012.43.7103
- Ulloa-Montoya F, Louahed J, Dizier B, Gruselle O, Spiessens B, Lehmann FF, et al. Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. J Clin Oncol 2013;31: 2388-95. https://doi.org/10.1200/JCO.2012.44.3762
- Butts C, Maksymiuk A, Goss G, Soulieres D, Marshall E, Cormier Y, et al. Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial. J Cancer Res Clin Oncol 2011;137: 1337-42. https://doi.org/10.1007/s00432-011-1003-3
- Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol 2014;15:59-68. https://doi.org/10.1016/S1470-2045(13)70510-2
- Nemunaitis J, Dillman RO, Schwarzenberger PO, Senzer N, Cunningham C, Cutler J, et al. Phase II study of belagenpuma-tucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol 2006;24:4721-30. https://doi.org/10.1200/JCO.2005.05.5335
- Nemunaitis J, Nemunaitis M, Senzer N, Snitz P, Bedell C, Kumar P, et al. Phase II trial of Belagenpumatucel-L, a TGF-beta2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients. Cancer Gene Ther 2009;16:620-4. https://doi.org/10.1038/cgt.2009.15
Cited by
- CIMAvax EGF (EGF-P64K) vaccine for the treatment of non-small-cell lung cancer vol.14, pp.10, 2014, https://doi.org/10.1586/14760584.2015.1079488
- Emerging immune checkpoints for cancer therapy vol.54, pp.10, 2014, https://doi.org/10.3109/0284186x.2015.1071918
- Lipid Nanoparticles Composed of Quaternary Amine–Tertiary Amine Cationic Lipid Combination (QTsome) for Therapeutic Delivery of AntimiR-21 for Lung Cancer vol.13, pp.2, 2016, https://doi.org/10.1021/acs.molpharmaceut.5b00878
- Quantitative and qualitative characterization of Two PD-L1 clones: SP263 and E1L3N vol.11, pp.1, 2014, https://doi.org/10.1186/s13000-016-0494-2
- Immunotherapy Comes of Age in Lung Cancer vol.18, pp.1, 2014, https://doi.org/10.1016/j.cllc.2016.06.006
- Kras and Tumor Immunity: Friend or Foe? vol.8, pp.9, 2014, https://doi.org/10.1101/cshperspect.a031849
- Clinical Characteristics and Prognostic Factors of Lung Cancer in Korea: A Pilot Study of Data from the Korean Nationwide Lung Cancer Registry vol.82, pp.2, 2014, https://doi.org/10.4046/trd.2017.0128
- Long Non-Coding RNAs (lncRNAs) in Response and Resistance to Cancer Immunosurveillance and Immunotherapy vol.10, pp.12, 2014, https://doi.org/10.3390/cells10123313